These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 1321910

  • 21. Antithrombotic activity of NSP-513, a novel selective phosphodiesterase 3 inhibitor, on femoral arterial thrombosis induced by physical stenosis and electrical current: comparison of antithrombotic and hemodynamic effects.
    Hirose H, Mashiko S, Kimura T, Ishida F, Mochizuki N, Nishibe T, Nishikibe M.
    J Cardiovasc Pharmacol; 2000 Apr; 35(4):586-94. PubMed ID: 10774790
    [Abstract] [Full Text] [Related]

  • 22. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
    Liao CH, Tzeng CC, Teng CM.
    Eur J Pharmacol; 1998 May 15; 349(1):107-14. PubMed ID: 9669503
    [Abstract] [Full Text] [Related]

  • 23. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
    Manns JM, Brenna KJ, Colman RW, Sheth SB.
    Thromb Haemost; 2002 May 15; 87(5):873-9. PubMed ID: 12038792
    [Abstract] [Full Text] [Related]

  • 24. 2-Aminochromones block human platelet aggregation by inhibiting cyclic AMP-dependent phosphodiesterase leading to reduced platelet phospholipase C activity.
    Benjamin CW, Lin AH, Morris J, Wishka DG, Gorman RR.
    J Pharmacol Exp Ther; 1993 Apr 15; 265(1):457-62. PubMed ID: 7682615
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of human platelet cyclic AMP phosphodiesterase and of platelet aggregation by a hemisynthetic flavonoid, amentoflavone hexaacetate.
    Beretz A, Briançon-Scheid F, Stierlé A, Corre G, Anton R, Cazenave JP.
    Biochem Pharmacol; 1986 Jan 15; 35(2):257-62. PubMed ID: 3002388
    [Abstract] [Full Text] [Related]

  • 26. A novel class of cardiotonic agents: synthesis and biological evaluation of pyridazino[4,5-b]indoles with cyclic AMP phosphodiesterases inhibiting properties.
    Monge A, Aldana I, Losa MJ, Font M, Castiella E, Frechilla D, Cenarruzabeitia E, Martinez de Irujo JJ, Lopez-Unzu J, Alberdi E.
    J Pharm Sci; 1993 May 15; 82(5):526-30. PubMed ID: 8395600
    [Abstract] [Full Text] [Related]

  • 27. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
    Lam SC, Guccione MA, Packham MA, Mustard JF.
    Thromb Haemost; 1982 Apr 30; 47(2):90-5. PubMed ID: 6285543
    [Abstract] [Full Text] [Related]

  • 28. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo.
    Minami N, Suzuki Y, Yamamoto M, Kihira H, Imai E, Wada H, Kimura Y, Ikeda Y, Shiku H, Nishikawa M.
    Life Sci; 1997 Apr 30; 61(25):PL 383-9. PubMed ID: 9416770
    [Abstract] [Full Text] [Related]

  • 29. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
    Cherng SC, Huang WH, Shiau CY, Lee AR, Chou TC.
    Eur J Pharmacol; 2006 Feb 17; 532(1-2):32-7. PubMed ID: 16457809
    [Abstract] [Full Text] [Related]

  • 30. 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.
    Cooper K, Fray MJ, Parry MJ, Richardson K, Steele J.
    J Med Chem; 1992 Aug 21; 35(17):3115-29. PubMed ID: 1507200
    [Abstract] [Full Text] [Related]

  • 31. (Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase.
    Lampe JW, Chou YL, Hanna RG, Di Meo SV, Erhardt PW, Hagedorn AA, Ingebretsen WR, Cantor E.
    J Med Chem; 1993 Apr 16; 36(8):1041-7. PubMed ID: 8386770
    [Abstract] [Full Text] [Related]

  • 32. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
    Alvarez R, Banerjee GL, Bruno JJ, Jones GL, Littschwager K, Strosberg AM, Venuti MC.
    Mol Pharmacol; 1986 Jun 16; 29(6):554-60. PubMed ID: 3012320
    [Abstract] [Full Text] [Related]

  • 33. Antithrombotic effects of BMY21190, an inhibitor of cAMP phosphodiesterase, in a canine model of coronary artery thrombosis.
    Minami M, Driscoll EM, Lucchesi BR.
    Jpn Circ J; 1993 Oct 16; 57(10):979-92. PubMed ID: 8230679
    [Abstract] [Full Text] [Related]

  • 34. Novel cAMP PDE III inhibitors: imidazo[4,5-b]pyridin-2(3H)-ones and thiazolo[4,5-b]pyridin-2(3H)-ones and their analogs.
    Singh B, Bacon ER, Robinson S, Fritz RK, Lesher GY, Kumar V, Dority JA, Reuman M, Kuo GH, Eissenstat MA.
    J Med Chem; 1994 Jan 21; 37(2):248-54. PubMed ID: 8295212
    [Abstract] [Full Text] [Related]

  • 35. Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity.
    Gillespie E.
    Biochem Pharmacol; 1988 Jul 15; 37(14):2866-8. PubMed ID: 2456068
    [No Abstract] [Full Text] [Related]

  • 36. 7-(Ethoxycarbonyl)-6,8-dimethyl-2-phenyl-1(2H)-phthalazinone derivatives: synthesis and inhibitory effects on platelet aggregation.
    Sugimoto A, Tanaka H, Eguchi Y, Ito S, Takashima Y, Ishikawa M.
    J Med Chem; 1984 Oct 15; 27(10):1300-5. PubMed ID: 6090662
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic.
    Meanwell NA, Rosenfeld MJ, Wright JJ, Brassard CL, Buchanan JO, Federici ME, Fleming JS, Seiler SM.
    J Med Chem; 1992 Jan 24; 35(2):389-97. PubMed ID: 1370696
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.